Diabetic Neuropathy PhD: Using Human Stem-Cell Models to Study APOE and Nerve Damage

Diabetic Neuropathy PhD: Using Human Stem-Cell Models to Study APOE and Nerve Damage

Quick Decision

This MRC FGx-DLA project tests whether APOE genotype changes how human sensory neurons and Schwann cells respond to diabetic-like stress. It compares e2/e2, e3/e3 and e4/e4 co-cultures, then swaps genotypes between the two cell types to separate cell-intrinsic effects from their interaction. Planned readouts include cell survival, neurite integrity, Schwann-cell wrapping and network activity, followed by long-read RNA analysis and candidate-gene perturbation or rescue.

The work suits applicants interested in stem-cell models, peripheral neurobiology and functional genomics. Clinical evidence linking APOE to diabetic neuropathy remains mixed, so the proposed experiments test a mechanism rather than confirm causation. Exeter lists 5 January 2027; earlier public information gives 8 December 2026. Confirm the deadline and international-fee terms in writing, then ask about cell-line quality, differentiation and stress protocols, assay scale and the cross-site supervision plan.

Research Problem and Doctoral Work

What Is Unsolved and Why It Matters

Diabetic peripheral neuropathy can begin with loss of small sensory fibres, and no treatment reliably halts or reverses it. Severity varies among people with similar glucose control, suggesting genetic and cellular mechanisms beyond glucose exposure alone. The project focuses on apolipoprotein E (APOE), which is associated with Alzheimer's disease risk but is also produced by non-myelinating Schwann cells that support small sensory fibres.

Human genetic evidence is not settled. A 2025 case-control study of 908 Lebanese adults with type 2 diabetes (382 with neuropathy and 526 without) reported higher neuropathy odds associated with ε4-containing APOE genotypes. Its cross-sectional, single-population design cannot establish causality or separate nerve-intrinsic effects from systemic lipid metabolism. An earlier review found a small, inconsistent literature. Older mouse work reports sensory nerve defects after apoE knockout and expression in non-myelinating Schwann cells; it supports plausibility, not human allele-specific diabetic causality. A genotype-controlled human-cell model could therefore address a meaningful mechanistic gap.

Work, Methods, and Potential Outputs

The project description sets out three linked objectives:

1. Compare same-genotype co-cultures. Establish human stem-cell-derived sensory neurons and Schwann cells on a shared genetic background carrying APOE e2/e2, e3/e3 or e4/e4. Both cell types in each first-stage co-culture carry the same genotype. Under high glucose or cytokine challenge, compare cell survival, nerve-fibre integrity, Schwann-cell ensheathment and network activity. Named assays include apoptosis measurements, microelectrode arrays (MEA) for network activity and patch clamp for single-neuron properties.
2. Localize the cell type carrying the effect. In mixed co-cultures, put e4 in the neurons while Schwann cells remain e3, then reverse the assignment. Comparing phenotype measures can distinguish a neuron-intrinsic effect, a Schwann-cell effect and an interaction between the two.
3. Identify and test candidate mechanisms. Use long-read RNA sequencing to examine full-length transcripts and isoform changes. Monoculture reference profiles are intended to help attribute co-culture changes to neurons or Schwann cells. The student will lead candidate selection and functionally perturb selected genes to ask whether a phenotype can be rescued; an industry partner is described as advising on druggability.

The intended outputs are a human neuron–glia model, evidence about which cell type or partnership mediates APOE-associated vulnerability, and candidate protective pathways. These are research aims, not promised findings or clinical treatments. The project mentions APOE lines from an existing collaboration, a sensory-neuron differentiation workflow with a manuscript in preparation, high-content imaging, super-resolution microscopy for ensheathment and Oxford Nanopore sequencing at Exeter. It does not specify line provenance and QC, the differentiation protocol, stress concentrations and duration, biological replicate numbers, sequencing scale, candidate-selection thresholds or rescue design. These details will affect feasibility and should be discussed before accepting.

School, Programme and Field Context

The named institution is the University of Exeter, with the project connected to its Living Systems Institute and Clinical and Biomedical Sciences. Exeter lists an MPhil/PhD route in Clinical and Biomedical Sciences and research themes including diabetes, neurodegeneration, molecular genetics, RNA biology and experimental medicine. The exact registration code, campus and any formal co-registration for this studentship are not specified; participation in a national training network does not by itself establish a joint degree.

Exeter's ranking page lists QS World University Rankings 2027 at #136 overall and THE World University Rankings 2027 at =157 overall. In REF 2021, Exeter reports 45% of Clinical Medicine (UoA 1) research at 4-star and 48% at 3-star; Psychology, Psychiatry and Neuroscience (UoA 4) at 53% and 39%; Biological Sciences (UoA 5) at 41% and 49%. These institution-wide and subject-wide measures are context, not evaluations of this group or project. The national FGx-DLA adds cohort training in functional genomics, statistics, bioinformatics, AI and machine learning, research integrity and career development. The specific schedule and cross-site expectations remain to be confirmed.

Supervisor and Lab Assessment

Supervisor Research Directions

The project names Dr Akshay Bhinge as lead supervisor and provides his Exeter contact. His group describes CRISPR-Cas9-edited patient stem cells, genomics, bioinformatics and high-throughput functional screens for neurodegeneration, particularly ALS and frontotemporal dementia. This provides relevant experience in human-cell models and functional analysis, but the group's public description is not a project-specific supervision plan. No co-supervisor, meeting cadence or division of responsibilities is stated.

Recent Important Publications

• Hawkins et al. (2022), “Upregulation of beta-catenin due to loss of miR-139 contributes to motor neuron death in ALS.” In an iPSC motor-neuron model, the authors link reduced miR-139 to WNT/beta-catenin activity and investigate its functional role in degeneration. This is a useful precedent for stem-cell disease modeling, RNA-level discovery and pathway validation. The disease and motor-neuron context differ from APOE in peripheral sensory neuron–Schwann-cell cultures.
• Hawkins et al. (2024), “ePRINT: exonuclease assisted mapping of protein-RNA interactions.” This method paper uses XRN1 exonuclease to map RNA-binding-protein interactions and targets. It signals active RNA-method development in the team, but ePRINT is not long-read RNA sequencing and does not validate the proposed diabetic-neuropathy model.
• Fusciardi et al. (2025), “Investigating the interaction of APOE4 with TDP43 mislocalisation in driving neurodegeneration.” This conference-supplement abstract describes early APOE4/TDP-43 work in iPSC-derived cortical neurons. It is adjacent because APOE4 is in scope, but protocols and APOE4 vector generation were still in progress. It is a preliminary abstract on a different disease and cell type, not evidence that this project's experiments or outcomes are already established.

Lab, Resources, and Collaboration Environment

The project specification names high-content imaging, super-resolution imaging, MEA, patch clamp and Oxford Nanopore long-read sequencing. General Living Systems Institute pages describe high-resolution/time-lapse and super-resolution imaging plus image-processing and data infrastructure. The project also states that isogenic APOE lines and a sensory-neuron protocol come through existing collaboration, and that three institutions and an industry partner are involved. Facility pages show institutional capability, not reserved access, staff training or a defined partner contribution. Ask who owns each protocol, which institution supplies which cells or assays, and whether the student will receive hands-on training in MEA, patch clamp and long-read analysis.

Funding, Application, and Living Cost

The current Exeter award page identifies this as a four-year MRC FGx-DLA studentship for autumn 2027 entry. It lists UK tuition fees, a stipend matching the UK Research Council minimum (£21,805/year in 2026/27, updated annually) and up to £5,000/year for research training and support. UKRI's current 2026/27 table also lists a £5,238 fee level; the 2027/28 stipend is not yet stated. The national programme's postgraduate page expressly says Exeter awardees do not need to supplement UKRI funding for international fees, whereas the local award page only spells out UK tuition. Read together, the national page provides the international-fee clarification; still ask for the written award terms and how annual fee changes are covered.

The live Exeter award page gives 5 January 2027. Earlier public information gave 8 December 2026. Because the earlier date comes first, use it as the safe planning deadline unless Exeter confirms in writing that the later date controls. No cutoff time or time zone is stated.

The 2026/27 stipend is about £1,817 per month. Exeter's broad 2026/27 guide suggests £1,300–£2,000 per month depending on lifestyle; its room finder lists an example postgraduate room at £124.74/week for 44 weeks. At the lower end, the stipend may leave some room for other costs; near the upper estimate, travel, deposits, utilities and unexpected expenses can make budgeting tight. The UK Student visa currently costs £558 and the Immigration Health Surcharge is additional; the award pages do not say that visa, surcharge or relocation costs are covered. Recheck current rates and personal visa requirements before applying.

The award page requires a minimum 2:1 honours degree or international equivalent in a relevant field. It lists genetics, molecular biology, biomedical science, human biology, biochemistry, medicine, healthcare professions, bioinformatics, computer science and statistics. IELTS is typically 7.0 overall with no component below 6.5, or an equivalent. Applicants submit one Exeter online application and the FGx-DLA questionnaire; they may list up to three preferences but should not submit multiple applications. Required material includes transcripts, a CV of no more than two pages, two references and English evidence when applicable. References should not come from the proposed supervisor team; shortlisted applicants must arrange for both references to be sent from institutional email accounts seven days before interview. Documents must be in English, with certified translations of qualifications/transcripts where needed.

Applicant Fit and Preparation

Formal requirements: a relevant 2:1-equivalent degree and English-language evidence when applicable. The published eligibility list is broad; no prior APOE/DPN research, electrophysiology or specific stem-cell technique is stated as a condition.

Useful experience to evidence, not formal prerequisites: cell or stem-cell culture; molecular biology/genome editing; neuronal or glial biology; electrophysiology or imaging; RNA sequencing; statistical or bioinformatic analysis. Because the project bridges experiments and transcriptomics, applicants can show how they plan controls, biological replicates and quantitative comparisons, even if they have not used every method.

Preparation: be ready to explain how same-genotype and mixed-genotype co-cultures separate cell-intrinsic from partnership effects, how a high-glucose/cytokine model would be controlled, and how long-read data could lead to a testable candidate. The application questionnaire asks for motivation, longer-term goals and research experience; a focused account of why this project needs both cell types and how you would approach uncertainty will be more useful than listing techniques alone.

Next Actions and Questions to Verify

Before Applying

• Check the live application portal and ask Exeter whether 8 December 2026 or 5 January 2027 is the controlling date, including cutoff time and time zone. Work to 8 December until resolved.
• Confirm the written fee offer: the national FGx-DLA page says Exeter awardees do not top up UKRI funding for international fees, while the local award page describes UK tuition. Ask how fee inflation and the full four-year period are treated.
• Verify degree equivalency, accepted English evidence and the single-application/up-to-three-preferences rule. Arrange transcripts, a two-page CV and two non-supervisor references early.

At Interview

• Which APOE-edited lines and genetic backgrounds are available, who generated them, and what identity/off-target QC has been completed?
• What differentiation protocol, maturity markers and cell-purity checks will be used for sensory neurons and Schwann cells? What glucose/cytokine doses, exposure durations, osmotic controls and biological replicate numbers are planned?
• Which endpoints will be applied across all genotype comparisons? How will MEA, patch-clamp and imaging data be combined without making the assay burden impractical?
• How will long-read sequencing distinguish cell-type-specific expression in mixed cultures? What sequencing scale, candidate threshold and functional rescue criteria are planned?
• What specifically will the other institutions and industry partner contribute, and which methods will the student learn directly?

Before Accepting an Offer

• Obtain the final award letter showing tuition coverage, stipend schedule, support-fund rules, international-fee treatment and responsibility for fee increases.
• Confirm registration route, campus, supervisor/co-supervisor roles, facility access and first-year experimental milestones.

Evidence and Sources

Project, programme, and doctoral route

• Official project description (PDF)
• Exeter MRC FGx-DLA award 6025
• Exeter MRC FGx-DLA programme page
• National postgraduate programme and international-fee guidance
• Clinical and Biomedical Sciences PhD route

Supervisor, team, and research environment

• Bhinge Group at the Living Systems Institute
• Akshay Bhinge's Exeter profile
• Living Systems Institute facilities
• Exeter rankings and league tables
• Exeter REF 2021 results

Papers and field evidence

• 2025 APOE genotype and diabetic neuropathy case-control study
• Review of APOE and diabetic peripheral neuropathy association
• APOE knockout mouse sensory nerve study
• Human stem-cell Schwann-cell model for diabetic neuropathy (2023)
• Neuron–Schwann co-culture under hyperglycemia (2022)
• Bhinge-associated iPSC motor-neuron study (2022)
• Bhinge-associated ePRINT RNA-method paper (2024)
• Preliminary APOE4/TDP-43 cortical-neuron conference abstract (2025)
• Isogenic APOE-edited iPSC lines
• Single-cell Schwann-cell metabolic-state study (2023)
• Review of iPSC models for peripheral neuropathy (2024)

Funding, costs, immigration, and careers

• UKRI stipend and fee levels
• Exeter 2026/27 indicative living-cost guide
• Exeter postgraduate accommodation examples
• UK Student visa guidance
• Skills England 2026 Life Sciences sector assessment
• UK Life Sciences Jobs Plan